NEW YORK: Merck & Co said it will buy Prometheus Biosciences Inc for about US$10.8bil (RM48bil), picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up its presence in immunology.
Merck will pay US$200 (RM880.40) per share for the California-based biotechnology company that specialises in treatments for autoimmune diseases.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
